SWITCH Trial Results

Question 1

In SWITCH 2, patients in the Tresiba arm had ____% lower rate of severe or blood glucose-confirmed symptomatic hypoglycemia.

Answer 1

In SWITCH 2, patients in the Tresiba arm had 30% lower rate of severe or blood glucose-confirmed symptomatic hypoglycemia.

Question 2

In SWITCH 2, what was the rate of nocturnal hypoglycemia in the Tresiba arm versus the glargine arm?

Answer 2

42% lower rate of severe or nocturnal hypoglycemia

Question 3

Which primary and seconday endpoints in SWITCH 2 were confirmed with statistical significance?

Answer 3

• superiority of Tresiba in rate of severe or blood glucose-confirmed symptomatic hypoglycemia during maintenance period
• superiority of Tresiba in rate of severe or blood glucose-confirmed symptomatic nocturnal hypoglycemia

Question 4

What study outcomes in SWITCH 2 were numerically lower in the Tresiba arm even though they did not reach statistical significance?

Answer 4

1. Percent of patients experiencing at least one episode of severe hypoglycemia during the maintenance period (1.6% for Tresiba, 2.4% for glargine)
2. rate of severe hypoglycemia events

Question 5

Was there a difference in the weight profile of the Tresiba and glargine arms in SWITCH 2?

Answer 5

No, weight changes were similar in both arms

Question 6

What were the numerical differences in weight change between the Tresiba and glargine arms?

Answer 6

• Tresiba 1.5 kg vs. glargine 1.8 kg in treatment period 1
• Tresiba 0.9 kg vs. glargine 0.5 kg in treatment period 2

Question 7

In SWITCH 2, what was the final dose of insulin in the Tresiba arm compared to the glargine arm?

Answer 7

Patients taking Tresiba used 4% less insulin than patients taking glargine.

Question 8

True or False: In SWITCH 1, Tresiba successfully met all primary endpoints, but failed to reach statistical significance in confirming secondary endpoints.

Answer 8

False, Tresiba successfully met all primary and secondary endpoints in SWITCH 1 and demonstrated noninferiority in rates of severe or symptomatic and nocturnal hypoglycemia versus glargine. Superiority was confirmed for the percentage of patients experiencing at least 1 episode of severe hypoglycemia.

Question 9

In SWITCH 1, patients in the Tresiba arm had ____% lower rate of severe or blood glucose-confirmed symptomatic hypoglycemia.

Answer 9

In SWITCH 1, patients in the Tresiba arm had 11% lower rate of severe or blood glucose-confirmed symptomatic hypoglycemia.

Question 10

In SWITCH 1, how much lower was the Tresiba arm in rates of severe or symptomatic nocturnal hypoglycemia rates compared to glargine?

Answer 10

36% lower rate of blood glucose-confirmed symptomatic nocturnal hypoglycemia

Question 11

What was the difference in severe hypoglycemia rates between Tresiba and glargine arms in SWITCH 1?

Answer 11

Tresiba arm had 35% lower rate of severe hypoglycemia

Question 12

In SWITCH 1, what were the differences in weight gain between the Tresiba and glargine arms?

Answer 12

Weight change was similar in both arms.

Question 13

In SWITCH 1, patients taking Tresiba used lower doses of insulin than those taking glargine. How much less?

Answer 13

3% lower dose of insulin in the Tresiba arm

Question 14

True or False: There were no clinical differences in the Tresiba and glargine arms in terms of percentage of patients experiencing at least 1 episode of severe hypoglycemia in SWITCH 1.

Answer 14

False, the percentage of patients experiencing at least 1 episode of severe hypoglycemia was significantly lower in the Tresiba arm (10.3%) than in the glargine arm (17.1%).

Question 15

What percentage of patients experienced at least 1 episode of severe hypoglycemia when comparing the Tresiba arm to the glargine arm in SWITCH 1?

Answer 15

10. 3% in Tresiba
11. 1% in glargine

Question 16

In SWITCH 2, what was the difference between Tresiba and glargine arms in the percentage of patients experiencing at least 1 episode of severe hypoglycemia during the maintenance period? Was the difference statistically significant?

Answer 16

• 1.6% of patients on Tresiba had at least 1 episode of severe hypo
• 2.4% of patients in glargine had at least 1 episode of severe hypo
• While the percentage of patients was numerically lower, it did not meet statistical significance.

Question 17

In SWITCH 2, what was the difference between Tresiba and glargine arms in the severe hypoglycemia event rate?

Answer 17

The severe hypoglycemia event rate was numerically lower with Tresiba, but it did not meet statistical significance.

Question 18

In SWITCH 2, what percentage of patients on Tresiba experienced at least 1 episode of severe hypoglycemia in the full treatment period? Glargine?

Answer 18

• 2.2% of patients taking Tresiba
• 3.9% of patients taking glargine